Results 41 to 50 of about 140,776 (178)
Dimethyl Fumarate (Tecfidera): A New Oral Agent for Multiple Sclerosis
, 2013 Objective: To describe the clinical evidence supporting the safety, efficacy, and clinical utility of oral dimethyl fumarate for the treatment of multiple sclerosis (MS).
Venci, Jineane V., Gandhi, Mona A.
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto +12 more
wiley +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019 Introduction Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing–remitting multiple sclerosis, which has been associated with gastrointestinal side ...
C Storm-Larsen +13 more
doaj +1 more source
Patients monitoring during treatment with Dimethyl fumarate (ORP-23) [PDF]
Neurology Letters, 2023 Dimethyl Fumarate (DMF) is a methyl ester of fumaric acid (chemical formula C6H8O4) that is hydrolyzed in the small intestine to the active metabolite monomethyl fumarate, approved for the treatment of RMS, and moderate to severe Psoriasis.
Ali Yousefi Pour
doaj
“Low‐Positive” MOG‐IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To determine the prevalence and clinical characteristics of patients with “low‐positive” (LP) MOG‐IgG (titres 1:160–1:320) among adults with a first demyelinating event (FDE) suggestive of multiple sclerosis (MS). Methods From the Barcelona CIS inception cohort, we included adult patients with serum collected ≤ 6 months from the FDE.
Javier Villacieros‐Álvarez +29 more
wiley +1 more source
A Solid-state NMR Study of Formoterol Fumarate [PDF]
, 2009 Spectra have been obtained for each of the three formoterol fumarate solvates diethanol, diisopropanol and dibenzyl alcohol and, with the aid of solution-state data and dipolar dephasing experiments, carbon-13 spectral assignments have been made.
Markwell, Andrew Fraser
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Progression independent of relapse activity is a major determinant of long‐term disability in multiple sclerosis, but its immunopathologic basis remains incompletely understood. We investigated whether relapse‐independent progression in radiologically stable relapsing–remitting multiple sclerosis is associated with distinct ...
Antonio Bruno +19 more
wiley +1 more source
, 2017 Multiple sclerosis (MS) is an autoimmunological disease leading to neurodegeneration. The etiology of the disease remains unknown, which strongly impedes the development of effective therapy.
Anika Jesion +6 more
core +1 more source
Cobalt‐Catalyzed C─N Bond Formation via Metal‐Hydride Hydrogen Atom Transfer (MHAT)
Angewandte Chemie, EarlyView.Cobalt‐catalyzed metal‐hydride hydrogen atom transfer (Co‐MHAT) converts simple alkenes into C─N bonds under mild, near‐neutral conditions. A shared Co─H‐initiated radical/organocobalt intermediate is channeled into radical trapping, radical‐polar crossover, or radical ligand transfer, unifying hydroamination, hydroazidation, hydroamidation, and remote
Arman Khosravi, Ming‐Yu Ngai
wiley +2 more sources
A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles
Molecules, 2021 Dimethyl fumarate is a cytoprotective and immunomodulatory drug used in the treatment of multiple sclerosis. We performed a bibliometric study examining the characteristics and trends of the top 100 cited articles that include dimethyl fumarate in the ...
Francisco Javier García-Fernández +6 more
doaj +1 more source